Novartis AG
ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST
Last updated:
Abstract:
Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.
Status:
Application
Type:
Utility
Filling date:
22 Feb 2021
Issue date:
11 Nov 2021